Stifel Financial
TVTX icon

Stifel Financial’s Travere Therapeutics TVTX Stock Holding History

Stifel Financial’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$607K Buy
10,682
+157
+1% +$6.96K ﹤0.01% 2850
2026
Q1 		$313K Sell
10,525
-2,235
-18% -$66.8K ﹤0.01% 3154
2025
Q4 		$488K Buy
+12,760
New +$415K ﹤0.01% 2873

Other funds holding TVTX

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Stifel Financial's TVTX Position: Q2 2026 in Review

Stifel Financial increased its Travere Therapeutics (TVTX) stake by 1.5% in Q2 2026, buying an estimated $6.96K and bringing the position to 10,682 shares worth $607K. The position accounts for ﹤0.01% of the portfolio, ranked #2850.

Stifel Financial first reported a position in TVTX in Q4 2025 and has held it in 3 quarters since. 321 funds tracked by Wall St. Rank hold TVTX as of Q2 2026.

  • Stifel Financial held 10,682 shares of Travere Therapeutics worth $607K as of Q2 2026.
  • Stifel Financial bought 157 Travere Therapeutics shares in Q2 2026, an estimated $6.96K.
  • Travere Therapeutics made up ﹤0.01% of Stifel Financial's portfolio in Q2 2026, its #2850 holding.
  • Stifel Financial first reported a position in Travere Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 321 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2026.

Based on Stifel Financial's 13F filing for Q2 2026, filed 12 Aug 2026.